Company news
Island Pharmaceuticals Ltd (ASX:ILA) news
Island Pharmaceuticals Ltd news releases on 6ix. Latest, Nov 18, 2024: Clinical trial progress update
Press releases — page 2
Clinical trial progress update
November 18, 2024
Island completes $3.5m Placement
October 3, 2024
Phase 2a PROTECT clinical trial dosed & Investor webinar
October 2, 2024
Binding LOI for proposed acquisition of Galidesivir
September 10, 2024
ISLA-101 Phase 2a/b clinical trial progresses
August 6, 2024
Non-binding term sheet signed with BioCryst
July 2, 2024
Investor Presentation
June 3, 2024
New data leads to proposed ISLA-101 Phase 2 efficiencies
June 3, 2024
Grant funding to directly support Phase 2a trial
May 7, 2024
Investor Presentation - Asia Bio Partnering
April 22, 2024
Positive data from ISLA-101 Single Ascending Dose study
April 15, 2024
Security Class Reinstatement to Quotation ILAO
April 1, 2024
Security Class Suspension from Quotation ILAO
March 26, 2024
Island Pharmaceuticals to raise $1.95 million for ISLA-101 development
February 27, 2024
Prospectus
February 25, 2024
$1.95million Fully Underwritten Rights Issue
February 25, 2024
Island investor presentation
February 6, 2024
Dosing complete in ISLA-101 SAD study
February 5, 2024
Quarterly Activity Report and Appendix 4C
January 30, 2024
Third cohort dosed in ISLA-101 Single Ascending Dose study
January 19, 2024
Approval to commence dosing 3rd cohort of ISLA-101 SAD study
December 21, 2023
R&D Tax Incentive loan facility secured with Radium Capital
December 14, 2023
Second cohort dosed in ISLA-101 Single Ascending Dose study
December 11, 2023
Island doses first cohort in ISLA-101 clinical trial
November 24, 2023
Screening commences for ISLA-101 Single Ascending Dose Study
November 12, 2023
Island receives R&D tax refund for FY2023
November 9, 2023
Island receives ethics approval for ISLA-101 study
November 6, 2023
ILA granted key Australian patent for ISLA-101
November 1, 2023
Quarterly Activity Report & Appendix 4C
October 29, 2023
ISLA-101 Single Ascending Dose study update
September 24, 2023
Island Pharmaceuticals granted key U.S. patent for ISLA-101
September 12, 2023
Appendix 4E & Annual Report
August 30, 2023
US grant funding to support ISLA-101 clinical development
July 6, 2023
Island receives FDA go-ahead for ISLA-101 program
May 15, 2023
Island submits responses to FDA questions for ISLA-101
April 16, 2023
ILA receives additional FDA feedback on IND for ISLA 101
January 31, 2023
Island receives FDA feedback on Phase 2a clinical study
January 19, 2023
ILA submits IND to US FDA for Phase 2a PEACH clinical trial
December 27, 2022
IRB approval received for ISLA101 Phase 2a clinical trial
December 14, 2022
ISLA101 drug product achieves stability milestone
December 14, 2022
ILA granted key Canadian patent for ISLA-101
November 15, 2022
Positive analytical results for ISLA-101 capsules
November 13, 2022
ISLA-101 manufacturing progress
October 27, 2022
ISLA-101 manufacturing and timeline update
June 15, 2022
Island executes PEACH clinical study CRO agreement
January 3, 2022
ISLA-101 Phase 2a clinical trial update
November 8, 2021
Island updates API agreement
September 20, 2021
Griffith Uni Anti-Viral Molecule Screening Collaboration
August 22, 2021
Island granted key Australian patent for ISLA-101
August 17, 2021
Island secures API - shortens timeline to clinical trials
July 22, 2021